Revolution and Allogene’s equity financings are a microcosm of biotech’s historic struggle.
ApexOnco Front Page
Recent articles
Lilly buys the dual-payload ADC specialist before it’s dosed a single patient.
The oncolytic virus vuso-vec is slapped with its second CRL.
The group impresses in ovarian and endometrial cancers.
After setbacks, cema-cel might have a path to approval in lymphoma.
Optimum-02 virtually replicates phase 1, and a filing will follow.
After opting in last year, Gilead picks up Kymera's KT-200.
The industry’s first ALK degrader starts its first human study.
